Launch of GATIFLO Tablet100mg a broad-spectrum oral antibacterial agent
June 11, 2002
Today (June 11), Kyorin Pharmaceutical Co., Ltd. (head office: Tokyo, president: Ikuo Ogihara) and Dainippon Pharmaceutical Co., Ltd. (head office: Osaka, president: Kenjiro Miyatake) have launched Gatiflo® Tablet 100 mg (non-proprietary name: gatifloxacin), a broad-spectrum oral antibacterial agent.
Recently, in the treatment of infectious diseases, physicians are facing the challenges involved in antibacterial agent including the appearance of microorganisms resistant against multiple drugs and the challenges to reduce various adverse drug reactions. Kyorin has engaged in the researches to develop a new quinolone with superior efficacy and safety to overcome such challenges, and finally discovered Gatiflo® Tablet 100 mg, an eight methoxy quinolone (EMQ), which has a methoxy group in the eighth position of the quinolone structure, for the first time in Japan.
Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.